The Optimal Sequence of Radiotherapy and Systematic Tyrosine Kinase Inhibitors in Treating Brain Metastases
Conditions
Keywords
Brain metastases, Radiotherapy, Targeted therapy
Brief summary
The investigators conducted a single institutional, retrospective cohort study to demonstrate the appropriate treatment strategy of upfront intracranial radiotherapy or upfront targeted therapy in patients with brain metastases, including an assessment of its feasibility and toxicity.
Interventions
None listed
Sponsors
Chinese Academy of Medical Sciences
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Had histologically proven primary cancer. * Had newly diagnosed brain metastases in contrast-enhanced MRI. * Brain metastases focus should be measurable. * All the patients should safely receive radiotherapy and/or systematic tyrosine kinase inhibitors. * Karnofsky performance score (KPS) ≥60 or KPS ≥40, but only caused by brain metastases.
Exclusion criteria
* Patients with prior intracranial local treatments, such as surgery and radiotherapy without dose prescription in detail * Patients with leptomeningeal metastases at first diagnosis. * Had synchronous or metachronous malignancies that might affect survival. * Had severe systemic diseases, abnormal conditions that might lead to incoordinate behavior during the implementation of clinical measures. * Had incomplete sociodemographic and/or clinicopathologic baseline data
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Intracranial progression-free survival | The interval from the start of initial intracranial treatment to first documented intracranial progression, or date of death from any cause, whichever came first, assessed up to 3 to 5 years | The survival time of patients before any intracranial progression |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival | The time from the date of initial intracranial treatment until death from any cause or censored on the last follow-up, whichever came first, assessed up to 3 to 5 years | The survival time of patients |
| Brain metastasis-specific survival | The interval from the start of initial intracranial treatment to death from brain metastases or censored on the last follow-up, whichever came first, assessed up to 3 to 5 years | The survival time of patients dead from brain metastases |
Countries
China
Outcome results
None listed